WO2007113261A1 - Process for preparing heterocyclic derivatives - Google Patents

Process for preparing heterocyclic derivatives Download PDF

Info

Publication number
WO2007113261A1
WO2007113261A1 PCT/EP2007/053118 EP2007053118W WO2007113261A1 WO 2007113261 A1 WO2007113261 A1 WO 2007113261A1 EP 2007053118 W EP2007053118 W EP 2007053118W WO 2007113261 A1 WO2007113261 A1 WO 2007113261A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compounds
formula
alkoxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/053118
Other languages
English (en)
French (fr)
Inventor
Sergio Bacchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES07727590.7T priority Critical patent/ES2443219T3/es
Priority to JP2009503555A priority patent/JP5167242B2/ja
Priority to CN200780019578XA priority patent/CN101454308B/zh
Priority to MX2008012876A priority patent/MX2008012876A/es
Priority to KR1020087026730A priority patent/KR101411124B1/ko
Priority to CA002648089A priority patent/CA2648089A1/en
Priority to EA200870405A priority patent/EA017304B1/ru
Priority to EP07727590.7A priority patent/EP2007747B1/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU2007233744A priority patent/AU2007233744B2/en
Priority to BRPI0710049-3A priority patent/BRPI0710049A2/pt
Publication of WO2007113261A1 publication Critical patent/WO2007113261A1/en
Priority to IL194389A priority patent/IL194389A0/en
Anticipated expiration legal-status Critical
Priority to NO20084414A priority patent/NO20084414L/no
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to a novel process, useful for preparing key intermediates in the synthesis of various compounds, among them compounds which are potent and specific antagonists of D3 receptors.
  • the present invention relates to a novel process for preparing thiazole or triazole derivatives of formula (I)
  • X may be Nitrogen or Sulfur
  • Het means aryl or heteroaryl; each of which may be substituted by 1 to 4 groups J selected from: halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl,
  • R 1 is a C1-C4 alkyl, -OR 3 Or -NR 3 R 4 ;
  • R 2 is hydrogen or C1 -C6 alkyl
  • R 3 is hydrogen or C1-C6 alkyl
  • R is H, C1-C6 alkyl, aryl, benzyl; each of which may be substituted by 1 to 4 groups J; according to the following Scheme 1 ⁇
  • step a means a reaction in basic conditions of compounds (MA) with 3- thiosemicarbazide derivatives, followed by a treatment with an inorganic base and n-propane phosphonic cyclic anhydride and final pH adjustement with inorganic acids to give compounds of formula (II).
  • C1-C6 alkyl refers to a linear or branched alkyl group containing from 1 to 6 carbon atoms; examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert butyl, pentyl or hexyl.
  • halogen refers to a fluorine, chlorine, bromine or iodine atom.
  • halo C1 -C6 alkyl means an alkyl group having one or more carbon atoms and wherein at least one hydrogen atom is replaced with halogen such as for example a trifluoromethyl group and the like.
  • C1 -C6 thioalkyl may be a linear or a branched chain thioalkyl group, for example thiomethyl, thioethyl, thiopropyl, thioisopropyl, thiobutyl, thiosec-butyl, thioferf-butyl and the like.
  • C2-C6 alkenyl defines straight or branched chain hydrocarbon radicals containing one or more double bond and having from 2 to 6 carbon atoms such as, for example, ethenyl, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2- butenyl or 3-hexenyl and the like.
  • C1 -C6 alkoxy group may be a linear or a branched chain alkoxy group, for example methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy or methyl prop-2-oxy and the like.
  • halo C1 -C6 alkoxy group may be a C1 -C6 alkoxy group as defined before substituted with at least one halogen, preferably fluorine, such as OCHF 2 , or OCF 3 .
  • C2-C6 alkynyl defines straight or branched chain hydrocarbon radicals containing one or more triple bond and having from 2 to 6 carbon atoms including acetylenyl, propynyl, 1-butynyl, 1 -pentynyl, 3-methyl-1 -butynyl and the like.
  • aryl means an aromatic carbocyclic moiety such as phenyl, biphenyl or naphthyl.
  • heteroaryl means an aromatic heterocycle ring of 5 to 10 members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono-and bicyclic ring systems.
  • heteroaryls include (but are not limited to) furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolinyl, isoquinolinyl, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, triazolyl, tetrazolyl, quinazolinyl, and benzodioxolyl.
  • 5-6 membered heterocycle means, according to the above definition, a 5-6 monocyclic heterocyclic ring which is either saturated, unsaturated or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized Heterocycles include heteroaryls as defined above
  • the heterocycle may be attached via any heteroatom or carbon atom.
  • the term includes (but is not limited to) morpholinyl, pyridinyl, pyrazinyl, pyrazolyl, thiazolyl, t ⁇ azolyl, imidazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
  • G is selected from a group consisting of: phenyl, py ⁇ dyl, benzothiazolyl, indazolyl,
  • • p is an integer ranging from 0 to 5; • R 1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C 1-4 alkyl, haloC ⁇ alkyl, C ⁇ alkoxy, haloC ⁇ alkoxy, C ⁇ alkanoyl; or corresponds to a group R 5 ,
  • R 2 is hydrogen or C 1 4 alkyl
  • R 3 is C 1-4 alkyl
  • R 4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 1 1 -membered bicyclic group, any of which groups is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of halogen, cyano, C 1 4 alkyl, 1IaIoC 1 4 alkyl, C 1 4 alkoxy, C ⁇ alkanoyl,
  • R 5 is a moiety selected from the group consisting of: isoxazolyl, -CH 2 -N-pyrrolyl, 1 ,1 -dioxido-2-isoth ⁇ azolid ⁇ nyl, thienyl, thiazolyl, pyridyl, 2-pyrrol ⁇ dinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C 1-4 alkyl, haloC ⁇ alkyl, C 1 ⁇ aIkOXy, C ⁇ alkanoyl; and when R 1 is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R 1 corresponds to R 5 , p is 1.
  • PB61926 is a moiety selected from the group consisting of: isoxazolyl, -CH 2 -N-pyrrolyl, 1 ,1 -dioxido-2-is
  • the process solves the above problems by using n-propane phosphonic cyclic anhydride, T3P, as condensation agent.
  • T3P was first used in the petide synthesis in 1980 by H. Wissmann (Angew. Chem., 1980, 92, 129) and is steadily gaining importance in organic synthesis because is less toxic and safer compared to other common condensation agents, such as DCC.
  • the reagent does not afford any water insoluble by-product.
  • T3P is used as 50% solution in ethyl acetate in the process of the present invention and does not need the isolation of the intermediate hydrazine-carbothiamide.
  • T3P is available as 50% solution in DMF (dimethylformamide) and may be employed in the process of the present invention.
  • the starting material, the heterocyclic carboxylic acid, generally commercially available or which may be prepared according to known methods in the literature, in an amount of 1 equivalent may be conveniently dissolved in the appropriate solvent (for example dimethylformamdide; ethyl acetate; acetonitrile and tetrahydrofurane and other polar aprotic solvent) and treated with a slightly excess of derivatives of 3-thiosemicarbazide (1.1 Oeq)., such as 4-methyl derivative. Then an organic base (e.g. triethylamine, diisopropylethylamine and possibly other aliphatic of aromatic amines) is added at RT.
  • the appropriate solvent for example dimethylformamdide; ethyl acetate; acetonitrile and tetrahydrofurane and other polar aprotic solvent
  • a slightly excess of derivatives of 3-thiosemicarbazide 1.1 Oeq.
  • an organic base e.g. trie
  • N-propane phosphonic cyclic anhydride (50% w/w in ethyl acetate) may be then added at a temperature ranging from from 0 to 40 degrees dropwise. In case the addition is made at about O 0 C, the temperature is then maintained below 15 0 C over 20-60 minutes. The resulting mixture was then stirred at 2O 0 C for 2-16 hours.
  • the mixture is then diluted with an aqueous solution of an appropriate inorganic base until basic pH was reached.
  • the suitable base may be selected among: potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide.
  • the resulting bi-phasic mixture (when observed) is then allowed separating and the upper organic layer discarded.
  • the aqueous layer is then heated to 50-90 0 C (internal temperature) for half an hour to several hours until reaction completion.
  • an appropriate mineral acid e.g HCI 37%) is then slowly added to adjust the pH as needed. (4 to 8).
  • the suspension is then generally stirred for 2-16 hours, then the solid was filtered, washed with pure water and dried in a vacuum oven at 40-60°C until dryness.
  • the final product is isolated from the aqueous mixture uncontaminated by phosphorous derivatives.
  • the mixture was diluted with NaOH 4 M (120.OmL). The resulting bi-phasic mixture was allowed separating and the upper organic layer discarded.
  • the suspension was stirred for 8 hours, then the solid was filtered and washed with water (6OmL), and it was dried in a vacuum oven at 4O 0 C overnight.
  • the suspension was cooled to 5 0 C and the solid was filtered and washed with water, and it was then dried in a vacuum oven at 4O 0 C overnight.
  • the solid was filtered and it was then dried in a vacuum oven at 4O 0 C overnight.
  • the solid was filtered and washed with water (3 times with 2OmL), and it was then dried in a vacuum oven at 4O 0 C overnight.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
PCT/EP2007/053118 2006-04-03 2007-03-30 Process for preparing heterocyclic derivatives Ceased WO2007113261A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EA200870405A EA017304B1 (ru) 2006-04-03 2007-03-30 Способ получения гетероциклических производных
CN200780019578XA CN101454308B (zh) 2006-04-03 2007-03-30 制备杂环衍生物的方法
MX2008012876A MX2008012876A (es) 2006-04-03 2007-03-30 Procedimiento para preparar derivados heterociclicos.
KR1020087026730A KR101411124B1 (ko) 2006-04-03 2007-03-30 헤테로시클릭 유도체의 제조 방법
CA002648089A CA2648089A1 (en) 2006-04-03 2007-03-30 Process for preparing heterocyclic derivatives
EP07727590.7A EP2007747B1 (en) 2006-04-03 2007-03-30 Process for preparing heterocyclic derivatives
AU2007233744A AU2007233744B2 (en) 2006-04-03 2007-03-30 Process for preparing heterocyclic derivatives
ES07727590.7T ES2443219T3 (es) 2006-04-03 2007-03-30 Procedimiento para la preparación de derivados heterocíclicos
JP2009503555A JP5167242B2 (ja) 2006-04-03 2007-03-30 複素環式誘導体の製造方法
BRPI0710049-3A BRPI0710049A2 (pt) 2006-04-03 2007-03-30 processo para preparação de derivados heterocìclicos
IL194389A IL194389A0 (en) 2006-04-03 2008-09-25 Process for preparing heterocyclic derivatives
NO20084414A NO20084414L (no) 2006-04-03 2008-10-21 Fremgangsmate for fremstilling av heterocykliske derivater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0607899.2A GB0607899D0 (en) 2006-04-03 2006-04-03 Process for preparing heterocyclic derivatives
GB0607899.2 2006-04-03

Publications (1)

Publication Number Publication Date
WO2007113261A1 true WO2007113261A1 (en) 2007-10-11

Family

ID=36581002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/053118 Ceased WO2007113261A1 (en) 2006-04-03 2007-03-30 Process for preparing heterocyclic derivatives

Country Status (18)

Country Link
US (2) US20070232808A1 (enExample)
EP (1) EP2007747B1 (enExample)
JP (1) JP5167242B2 (enExample)
KR (1) KR101411124B1 (enExample)
CN (1) CN101454308B (enExample)
AU (1) AU2007233744B2 (enExample)
BR (1) BRPI0710049A2 (enExample)
CA (1) CA2648089A1 (enExample)
CR (1) CR10351A (enExample)
EA (1) EA017304B1 (enExample)
ES (1) ES2443219T3 (enExample)
GB (1) GB0607899D0 (enExample)
IL (1) IL194389A0 (enExample)
MA (1) MA30354B1 (enExample)
MX (1) MX2008012876A (enExample)
NO (1) NO20084414L (enExample)
WO (1) WO2007113261A1 (enExample)
ZA (1) ZA200808107B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3995C2 (ro) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Utilizare a di(µ-Ofenoxi)-di{[2-(4-aminobenzensulfamido)-5-etil-1,3,4-tiadiazol]-3,5-dibromosalicilidentiosemicarbazonato(-1)-cupru} în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
IT201700041723A1 (it) 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6
CN106866657A (zh) * 2017-04-25 2017-06-20 成都倍特药业有限公司 一种麦角新碱的制备方法
US9862675B1 (en) 2017-07-05 2018-01-09 King Fahd University Of Petroleum And Minerals Method of N-formylating amines with a phosphonic anhydride
JP2023537052A (ja) 2020-08-07 2023-08-30 イタルファルマコ ソシエタ ペル アチオニ 新規オキサジアゾール系の選択的hdac6阻害剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
WO2005080382A1 (en) 2004-02-23 2005-09-01 Glaxo Group Limited Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10033337A1 (de) * 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
AU1697502A (en) * 2000-10-20 2002-04-29 Rhodia Acetow Gmbh Highly compressed filter tow bales
GB0517193D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
WO2005080382A1 (en) 2004-02-23 2005-09-01 Glaxo Group Limited Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ECH-CHAHAD A ET AL: "An expeditious hydroxyamidation of carboxylic acids", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 46, no. 31, 1 August 2005 (2005-08-01), pages 5113 - 5115, XP004963778, ISSN: 0040-4039 *
H. WISSMANN, ANGEW. CHEM., vol. 92, 1980, pages 129

Also Published As

Publication number Publication date
CN101454308B (zh) 2013-05-08
KR101411124B1 (ko) 2014-06-25
JP5167242B2 (ja) 2013-03-21
US20100048895A1 (en) 2010-02-25
US20070232808A1 (en) 2007-10-04
CN101454308A (zh) 2009-06-10
JP2009532428A (ja) 2009-09-10
EP2007747B1 (en) 2013-11-20
AU2007233744B2 (en) 2012-09-06
EP2007747A1 (en) 2008-12-31
CA2648089A1 (en) 2007-10-11
BRPI0710049A2 (pt) 2011-08-02
AU2007233744A1 (en) 2007-10-11
IL194389A0 (en) 2009-08-03
EA200870405A1 (ru) 2009-04-28
NO20084414L (no) 2008-10-28
KR20080108328A (ko) 2008-12-12
GB0607899D0 (en) 2006-05-31
US7838680B2 (en) 2010-11-23
MX2008012876A (es) 2008-10-13
EA017304B1 (ru) 2012-11-30
CR10351A (es) 2008-10-29
MA30354B1 (fr) 2009-04-01
ZA200808107B (en) 2009-10-28
ES2443219T3 (es) 2014-02-18

Similar Documents

Publication Publication Date Title
AU2011261263C1 (en) Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer
KR102284938B1 (ko) 다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법
KR102573454B1 (ko) 치환 3-아릴-5-트리플루오로메틸-1,2,4-옥사디아졸의 제조
AU2004232551A1 (en) Condensed N-heterocyclic compounds and their use as CRF receptor antagonists
JPH0784470B2 (ja) 活性化合物、その製法及びそれを含む医薬組成物
CA2772105A1 (en) Fused triazole amines as p2x7 modulators
EP2007747B1 (en) Process for preparing heterocyclic derivatives
JPWO2014119636A1 (ja) Hiv複製阻害剤
WO2008085117A1 (en) Pyridine compounds and their use as p2y12 antagonists.
EP2928472B1 (en) Process for making reverse transcriptase inhibitors
KR102541668B1 (ko) 1,2,4-옥사디아졸 유도체의 제조 방법
WO2011012600A1 (en) Ring-annulated dihydropyrrolo[2,l-a]isoquinolines
AU2007270086A1 (en) New pyridine analogues
WO2013050341A1 (en) Azabenzoxazine derivatives as crac modulators
WO2013050270A1 (en) Benzoxazine derivatives as crac modulators
JP2008534642A (ja) 二環式化合物の調製方法
MXPA05006588A (es) Compuestos de pirazol como derivados antagonistas del receptor de la integrina.
Hill 5.2 Dimroth Triazole Synthesis
WO2016143654A1 (ja) 1,2,4-オキサジアゾール誘導体の製造方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780019578.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07727590

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007233744

Country of ref document: AU

Ref document number: 571449

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 194389

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 8109/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008091614

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 12008502216

Country of ref document: PH

Ref document number: 2648089

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012876

Country of ref document: MX

Ref document number: 2009503555

Country of ref document: JP

Ref document number: 08105789

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: CR2008-010351

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2007233744

Country of ref document: AU

Date of ref document: 20070330

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007727590

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087026730

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: DZP2008000647

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 200870405

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0710049

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080929